 |
 |
On 22 Aug 2001, at 13:17, Perry Cohen wrote: > > The latest word is that in about a week the Amgen project staff will > present the detailed findings from phase II to an internal committee > which will presumably make recommendations about the next steps for the > NIL-A medication. The decision about whether and how to proceed is taken > in a larger context of the company's opportunities and other priorities. > There is no indication what the recommendation will be or when a > decision will be taken. Hi Perry, Thank you for reminding us that this clinical trial is nearing completion. Here is an interesting web page you might like to check out. Clinical Development for Parkinson's disease Search Clinical Research Studies currently enrolling patients for Parkinson's disease http://www.biospace.com/ct/results.cfm?indication=171 Cheers ...... murray [log in to unmask] ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn